A2B543 / A2 Biotherap - LARVOL DELTA

A logic-gated chimeric antigen receptor T-cell (CAR T) therapy with an armored, membrane-tethered IL-12 booster in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity (LOH): EVEREST-2, a phase 1/2 study. (ASCO 2026) - P, P1/2 | "Early efficacy results include the first ever reported complete response in a patient with non-small cell lung cancer following treatment with a CAR T-cell therapy (A2B694). The phase 1 primary objective is to evaluate the safety and tolerability of A2B543 and identify a recommended phase 2 dose (RP2D). The phase 2 primary objective is to assess overall response rate."

CAR T-Cell Therapy • Clinical • Metastases • P1/2 data • Idiopathic Arthritis • Lung Cancer • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • HLA-A • IL12A • MSLN

EVEREST-2 Study Arm 2: Enrollment Update on A2B543 (Businesswire) - "The first A2B543 patient was enrolled to dose level 1 in January 2026, and dose escalation continues."

Enrollment status • Solid Tumor

A2 Biotherapeutics to Highlight Progress of CAR T-Cell Clinical Programs in Three Poster Presentations During the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting (Businesswire) - "A2 Bio will present two posters from the ongoing phase 1/2 EVEREST-2 study: The first provides the safety and efficacy of A2B694, a logic-gated mesothelin (MSLN)-targeted Tmod chimeric antigen receptor T-cell (CAR T) therapy. The second is a trials-in-progress poster about A2B543, which uses the same logic-gated construct as A2B694 but also includes a membrane-tethered IL-12 booster. A third poster describes modules based on IL-12 and other molecules that boost potency and preserve selectivity of Tmod-based precision cell therapies."

Clinical data • Trial status • Solid Tumor

A2 Biotherapeutics Receives U.S. FDA Fast Track Designation for A2B543, a Logic-Gated CAR T-Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster (Businesswire) - "A2B543 is being investigated in the ongoing EVEREST-2 clinical study (NCT06051695) which is evaluating the safety and efficacy of A2B694 (Arm 1) and A2B543 (Arm 2) autologous logic-gated investigational cell therapies in patients with colorectal cancer, pancreatic cancer, non-small cell lung cancer, ovarian cancer, mesothelioma, and other solid tumors that express MSLN and have lost HLA-A*02 expression."

Fast track • Colorectal Cancer • Mesothelioma • Non Small Cell Lung Cancer • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

A2 Biotherapeutics…announced the first patient dosed with A2B543, initiating the second arm of the Phase 1/2 EVEREST-2 study (NCT06051695) (Businesswire)

Trial status • Solid Tumor

A2 Biotherapeutics Announces FDA Clearance of IND for A2B543 for Treatment of Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors that Express Mesothelin and Have Lost HLA-A*02 Expression (A2 Bio Press Release) - "It will be evaluated as a second arm of the EVEREST-2 master protocol (NCT06051695) in patients with colorectal cancer, pancreatic cancer, non-small cell lung cancer, ovarian cancer, mesothelioma, and other solid tumors that express mesothelin (MSLN) and have lost HLA-A*02 expression."

IND • Colorectal Cancer • Mesothelioma • Non Small Cell Lung Cancer • Ovarian Cancer • Pancreatic Cancer